Eli Lilly (LLY.US) - a non-covalent BTK inhibitor - applies for new indication for "picotamide"

Zhitong Finance APP learned that on June 18th, according to the CDE website, Eli Lilly (LLY.US) has applied for a new indication for its venetoclax tablets. It is speculated that the indication for this application is adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior therapies.